Pfenex, Inc. receives contract for candidate anthrax vaccine

Pfenex, Inc., was one of several organizations that recently signed one of eight contracts with the U.S. Department of Health and Human Services’ Biomedical Advanced Research Development Authority worth between $55 million and $100 million over the next three years.

Pfenex will apply its Pfenex Expression Technology Platform to develop optimized bioprocesses for the high-yield production of a candidate anthrax vaccine, according to

The Public Service Health Act, as amended by the Pandemic and All-Hazards Preparedness Act authorized BARDA, identifies solutions to potential public health emergencies and awards contracts to those projects.

BARDA believes these contracts will help advance tools and techniques that will reduce the time and cost of the testing and production of medical countermeasures and make them safer and easier to use.

Other recipients of the eight contracts include VaxDesign of Orlando, Florida; PATH of Seattle, Washington; Infectious Disease Research Institute of Seattle, Washington; Novartis Vaccines and Diagnostics of Cambridge, Massachusetts; Rapid BioSystems of Bedford, Massachusetts; 3M of St. Paul, Minnesota; and Northup Grumman Security Systems of Baltimore, Maryland.

The contracts will either directly support the evaluation and development of a specific type of countermeasure or have broader applicability that would benefit the United States’ countermeasure infrastructure, reports.

A broad agency announcement contracting tool was used in awarding the contracts. The BAA looks for proposals in four categories of countermeasure development and is then used to identify platform technologies that fit several products or programs.

Organizations in this Story


Want to get notified whenever we write about 3M ?
Next time we write about 3M, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.